AVADEL PHARMA Stock Analysis, Valuation (NASDAQ:AVDL)

Add to My Stocks
$8.78 $0.12 (1.39%) AVDL stock closing price Aug 18, 2017 (Closing)
Watch Robo Advisor Video of AVDL Stock Analysis
AVADEL PHARMA
Updated on : Aug 18, 2017
previous close
AVDL 8.8 (0%)
S&P 500 2425.6 (0%)
Closing Price On: Aug 18, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
38.1%
Operating Profit
Operating Margin:
13.7%
Sector Average:
-0.4%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
0.8M
Debt/Equity Ratio:
 0.01
Compared to the industry
Cash Flow
Operating cash flow:
$25.3M
Net Income:
$25.4M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Low Debt Burden
FCF Margin
PS Valuation
Net Margins
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
AVDL PS :
2.1
Industry PS :
5.1
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-32.3%
Return on Equity:
-23.4%
Free Cash Flow Margin:
47.6%
Double Tap To Exit Full Screen
0:00
/

AVADEL PHARMA Analysis Video

9 5 2

View AVADEL PHARMA stock analysis video. This is our AVDL analyst opinion covering the buy and sell arguments for AVDL stock.

AVADEL PHARMA Stock Rating (3.9/5)

Our AVADEL PHARMA stock opinion is based on fundamentals of the company. This AVADEL PHARMA stock analysis is based on latest 2017 Q2 earnings. The stock price analysis takes into account the company's valuation metrics.

Should you buy AVDL stock?

  • AVADEL PHARMA sales grew by 45% year on year in 2017 Q1.
  • The company saw a significant growth in revenue with a 5 year CAGR of 38.1%.
  • AVADEL PHARMA's average operating margin of 13.7% was exceptional.
  • AVADEL PHARMA has a lower debt burden than its peers in the Medical sector, with a debt/equity ratio of  0.01.
  • AVDL stock is trading at a favorable price to sales multiple of 2.1 as against the Medical-Drugs industry average multiple of 5.1.
  • AVADEL PHARMA has a healthy FCF (Free Cash Flow) margin of 47.6%.

Should you sell AVDL stock?

  • Over the last 12 months, AVADEL PHARMA had an average Net loss of -7.3%.
  • AVADEL PHARMA's negative ROIC of -32.3% indicates operational inefficiency.
  • AVADEL PHARMA has a negative ROE (Return On Equity) of -23.4%, indicating the company is not profitable.

Comments on this video and AVADEL PHARMA stock